AVEO prices offering to raise $50m for commercialization of tivozanib
This article was originally published in Scrip
Executive Summary
AVEO Pharmaceuticals began selling 6.7 million shares of common stock at $7.50 per share on 17 January - at a discount to the stock's previous closing price of $8.12 - to raise $50 million in gross proceeds for working capital, including funds for the commercialization of tivozanib in the treatment of advanced renal cell carcinoma (RCC).